Skip to content

OZONE_EXO: Comparative Analysis of Protocols for Dental Exactions in Patients at Risk of MRONJ: Case-control Study

Comparative Analysis of Different Protocols for Dental Exactions in Patients at Risk of MRONJ: Case-control Study

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06072404
Acronym
OZONE_EXO
Enrollment
117
Registered
2023-10-10
Start date
2018-02-01
Completion date
2020-03-30
Last updated
2025-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MEDICATION RELATED OSTEONECROSIS OF THE JAW

Keywords

MRONJ, Osteonecrosis, Ozone therapy, Jaw, Antiresorptive, Antiangiogenic drugs, Adverse event

Brief summary

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is also a potentially painful and debilitating condition. Today, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established. Among non-invasive procedures to treat MRONJ, the use of medical ozone (O3) arises for its properties and has been deployed and evaluated. O3 has generally proven to play a role in the treatment of chronic, nonhealing, or ischemic wounds, due to its antimicrobial and anti-oxidant properties and to bio-stimulation; it has been extensively used for different medical approaches and purposes. In oral cavity, local applications are carried out by ozonized water (i.e. spray or compress) or gel. The aim of this study was to carry out a case-control study in order to compare two different protocols of dental extractions in patients at risk of MRONJ, with and without infiltration of a mixture of oxygen-ozone. All the cases in our study are cancer and oncologic and osteometabolic patients undergoing high-risk therapy for MRONJ (antiresorptive and antiangiogenic drugs) who require dental extractions with a poor prognosis. During the first examination (T0), medical, pharmacological, and dental history of patients are recorded. Data collected are: (1) age; (2) gender; (3) indications for use, type, cumulative dose and duration of MRONJ-related drugs; (4); history of chemotherapy; (5) other medications; (6) other diseases; (7) smoking. For each patient, an orthopantomography and a cone beam computed tomography of the teeth are performed only if indicated.

Detailed description

The enrolled patients were randomly divided into two groups: Group A: consisting of 38 patients (undergoing ozone treatment) (OZONE\_EXO) intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site in patients at risk of medication-induced osteonecrosis of the jaw (ONJ). Group B: comprising 79 controls (not undergoing ozone treatment).(NO\_OZONE\_EXO) Tooth extraction in patients at risk of medication-induced osteonecrosis of the jaw (ONJ) without the use of ozone application. Following the same approach as in Group A, patients in Group B underwent additional follow-up visits at T1 (3-5 days), T2 (14 days), and T3 (6 weeks) post-extraction, in accordance with Inflammatory - P roliferative - Remodeling (IPR) Wound Healing Scale. the IPR scale score, to meticulously monitor surgical wound healing and record pain intensity using the NRS scale, rather than the originally planned VAS scale, for enhanced ease of use \[22\]. The IPR scale provided a comprehensive assessment of wound healing through distinct subscales, each ranging from 0 to 1, resulting in a total score ranging from 0 to 16. These subscales evaluated the inflammatory response, proliferative response, and remodeling process. At the conclusion of the follow-up period, the total IPR score was computed, with scores spanning from 0 to 16. Scores of 0-4 denoted poor healings, scores of 5-10 indicated acceptable healing, while scores of 11-16 suggested excellent healing.

Interventions

BIOLOGICALOxigenOzone_Insufflation

intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.

Sponsors

University of Palermo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* age ≥ 18 yrs * patients at risk of developing MRONJ for previous or current administration of drugs related * extraction of teeth with a poor prognosis due to severe decay and/or periodontitis

Exclusion criteria

* previous radiation in the head and neck area * neoplastic involvement of the jaw * previous MRONJ diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase3-5 days after the interventionThe inflammatory phase is evaluated 3-5 days after tissue injury on the basis of eight parameters, measured on a 9-point scale (0-8): bleeding (spontaneously or on palpation), granulation tissue, hematoma, tissue color, incision margins, suppuration, edema, and pain. A score of 5-8 indicates a successful inflammatory phase
Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Proliferative Phase:14 days after the interventionThe proliferative phase is evaluated 14 days after tissue injury on the basis of five parameters, measured on a 6-point scale (0-5): re-epithelialization, tissue color, scar, suppuration, and pain. A score of 3-5 score indicates successful healing.
Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Remodelling Phase6 weeks after the interventionThe remodeling phase is evaluated 6 weeks after tissue injury on the basis of three parameters, measured on a 4-point scale (0-3): scar, tissue color, and pain. A score of 2-3 indicates successful healing

Secondary

MeasureTime frameDescription
Healing Evaluation Using IPR Scale: Total Process6 weekThe total score of the IPR scale ranges from 0 to 16:0-4 indicates poor healing; 5-10, acceptable healing; and 11-16, excellent healing The inflammatory phase carries the greatest weight in the final score because its impairment can jeopardize the entire series of biologic events leading to early wound healing.

Countries

Italy

Participant flow

Recruitment details

Potential participants were identified among patients attending the Oral Medicine with Dentistry for Fragile Patients Unit at the Paolo Giaccone Policlinico University Hospital of Palermo from February 2018 to March 2020. Patients were approached with written and verbal information about the study.

Pre-assignment details

The study recruited 117 patients (27 male and 90 female) and were randomized to treatment.

Participants by arm

ArmCount
Group A (OZONE_EXO)
intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site in patients at risk of medication-induced osteonecrosis of the jaw (ONJ). OxigenOzone\_Insufflation: intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
38
Group B (NO_OZONE_EXO)
Tooth extraction in patients at risk of medication-induced osteonecrosis of the jaw (ONJ) without the use of ozone application.
79
Total117

Baseline characteristics

CharacteristicGroup A (OZONE_EXO)Group B (NO_OZONE_EXO)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
38 Participants79 Participants117 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
38 Participants79 Participants117 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Region of Enrollment
Italy
38 Participants79 Participants117 Participants
Sex: Female, Male
Female
27 Participants63 Participants90 Participants
Sex: Female, Male
Male
11 Participants16 Participants27 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 380 / 79
other
Total, other adverse events
0 / 380 / 79
serious
Total, serious adverse events
0 / 380 / 79

Outcome results

Primary

Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase

The inflammatory phase is evaluated 3-5 days after tissue injury on the basis of eight parameters, measured on a 9-point scale (0-8): bleeding (spontaneously or on palpation), granulation tissue, hematoma, tissue color, incision margins, suppuration, edema, and pain. A score of 5-8 indicates a successful inflammatory phase

Time frame: 3-5 days after the intervention

ArmMeasureValue (MEAN)Dispersion
Group A (OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase2 score on a scaleStandard Deviation 0.87
Group B (NO_OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase2.49 score on a scaleStandard Deviation 0.875
Primary

Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Proliferative Phase:

The proliferative phase is evaluated 14 days after tissue injury on the basis of five parameters, measured on a 6-point scale (0-5): re-epithelialization, tissue color, scar, suppuration, and pain. A score of 3-5 score indicates successful healing.

Time frame: 14 days after the intervention

ArmMeasureValue (MEAN)Dispersion
Group A (OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Proliferative Phase:4.24 score on a scaleStandard Deviation 1.51
Group B (NO_OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Proliferative Phase:3.7 score on a scaleStandard Deviation 1.02
Primary

Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Remodelling Phase

The remodeling phase is evaluated 6 weeks after tissue injury on the basis of three parameters, measured on a 4-point scale (0-3): scar, tissue color, and pain. A score of 2-3 indicates successful healing

Time frame: 6 weeks after the intervention

ArmMeasureValue (MEAN)Dispersion
Group A (OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Remodelling Phase3 score on a scaleStandard Deviation 0
Group B (NO_OZONE_EXO)Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Remodelling Phase2.96 score on a scaleStandard Deviation 0.192
Secondary

Healing Evaluation Using IPR Scale: Total Process

The total score of the IPR scale ranges from 0 to 16:0-4 indicates poor healing; 5-10, acceptable healing; and 11-16, excellent healing The inflammatory phase carries the greatest weight in the final score because its impairment can jeopardize the entire series of biologic events leading to early wound healing.

Time frame: 6 week

ArmMeasureValue (MEAN)Dispersion
Group A (OZONE_EXO)Healing Evaluation Using IPR Scale: Total Process9.37 score on a scaleStandard Deviation 1.79
Group B (NO_OZONE_EXO)Healing Evaluation Using IPR Scale: Total Process9.15 score on a scaleStandard Deviation 1.38

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026